Literature DB >> 25162309

Iodine quantification to distinguish clear cell from papillary renal cell carcinoma at dual-energy multidetector CT: a multireader diagnostic performance study.

Achille Mileto1, Daniele Marin, Marcela Alfaro-Cordoba, Juan Carlos Ramirez-Giraldo, Christian D Eusemann, Emanuele Scribano, Alfredo Blandino, Silvio Mazziotti, Giorgio Ascenti.   

Abstract

PURPOSE: To investigate whether dual-energy multidetector row computed tomographic (CT) imaging with iodine quantification is able to distinguish between clear cell and papillary renal cell carcinoma ( RCC renal cell carcinoma ) subtypes.
MATERIALS AND METHODS: In this retrospective, HIPAA-compliant, institutional review board-approved study, 88 patients (57 men, 31 women) with diagnosis of either clear cell or papillary RCC renal cell carcinoma at pathologic analysis, who underwent contrast material-enhanced dual-energy nephrographic phase study between December 2007 and June 2013, were included. Five readers, blinded to pathologic diagnosis, independently evaluated all cases by determining the lesion iodine concentration on color-coded iodine maps. The receiving operating characteristic curve analysis was adopted to estimate the optimal threshold for discriminating between clear cell and papillary RCC renal cell carcinoma , and results were validated by using a leave-one-out cross-validation. Interobserver agreement was assessed by using an intraclass correlation coefficient. The correlation between tumor iodine concentration and tumor grade was investigated.
RESULTS: A tumor iodine concentration of 0.9 mg/mL represented the optimal threshold to discriminate between clear cell and papillary RCC renal cell carcinoma , and it yielded the following: sensitivity, 98.2% (987 of 1005 [95% confidence interval: 97.7%, 98.7%]); specificity, 86.3% (272 of 315 [95% confidence interval: 85.0%, 87.7%]); positive predictive value, 95.8% (987 of 1030 [95% confidence interval: 95.0%, 96.6%]); negative predictive value, 93.7% (272 of 290 [95% confidence interval: 92.8%, 94.7%]); overall accuracy of 95.3% (1259 of 1320 [95% confidence interval: 94.6%, 96.2%]), with an area under the curve of 0.923 (95% confidence interval: 0.913, 0.933). An excellent agreement was found among the five readers in measured tumor iodine concentration (intraclass correlation coefficient, 0.9990 [95% confidence interval: 0. 9987, 0.9993). A significant correlation was found between tumor iodine concentration and tumor grade for both clear cell (τ = 0.85; P < .001) and papillary RCC renal cell carcinoma (τ = 0.53; P < .001).
CONCLUSION: Dual-energy multidetector CT with iodine quantification can be used to distinguish between clear cell and papillary RCC renal cell carcinoma , and it provides insights regarding the tumor grade. © RSNA, 2014.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25162309     DOI: 10.1148/radiol.14140171

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  34 in total

Review 1.  Advances in medical imaging for the diagnosis and management of common genitourinary cancers.

Authors:  Mohammad H Bagheri; Mark A Ahlman; Liza Lindenberg; Baris Turkbey; Jeffrey Lin; Ali Cahid Civelek; Ashkan A Malayeri; Piyush K Agarwal; Peter L Choyke; Les R Folio; Andrea B Apolo
Journal:  Urol Oncol       Date:  2017-05-12       Impact factor: 3.498

Review 2.  Use of dual-energy CT for renal mass assessment.

Authors:  Shanigarn Thiravit; Christina Brunnquell; Larry M Cai; Mena Flemon; Achille Mileto
Journal:  Eur Radiol       Date:  2020-11-18       Impact factor: 5.315

3.  Dual Energy Differential Phase Contrast CT (DE-DPC-CT) Imaging.

Authors:  Xu Ji; Ran Zhang; Ke Li; Guang-Hong Chen
Journal:  IEEE Trans Med Imaging       Date:  2020-10-28       Impact factor: 10.048

4.  Inter-scan and inter-scanner variation of quantitative dual-energy CT: evaluation with three different scanner types.

Authors:  Simon Lennartz; Anushri Parakh; Jinjin Cao; David Zopfs; Nils Große Hokamp; Avinash Kambadakone
Journal:  Eur Radiol       Date:  2021-01-14       Impact factor: 5.315

5.  Quantitative myocardial perfusion with stress dual-energy CT: iodine concentration differences between normal and ischemic or necrotic myocardium. Initial experience.

Authors:  Carlos Delgado Sánchez-Gracián; Roque Oca Pernas; Carmen Trinidad López; Eloísa Santos Armentia; Antonio Vaamonde Liste; María Vázquez Caamaño; Gonzalo Tardáguila de la Fuente
Journal:  Eur Radiol       Date:  2015-12-23       Impact factor: 5.315

6.  Determination of Optimal Image Type and Lowest Detectable Concentration for Iodine Detection on a Photon Counting Detector-Based Multi-Energy CT System.

Authors:  Wei Zhou; Rachel Schornak; Gregory Michalak; Jayse Weaver; Dilbar Abdurakhimova; Andrea Ferrero; Kenneth A Fetterly; Cynthia H McCollough; Shuai Leng
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2018-03

Review 7.  [Noninvasive phenotyping of renal tumors-current state of the art].

Authors:  Hubert Stefan Bickel
Journal:  Radiologe       Date:  2018-10       Impact factor: 0.635

8.  How accurate and precise are CT based measurements of iodine concentration? A comparison of the minimum detectable concentration difference among single source and dual source dual energy CT in a phantom study.

Authors:  André Euler; Justin Solomon; Maciej A Mazurowski; Ehsan Samei; Rendon C Nelson
Journal:  Eur Radiol       Date:  2018-10-01       Impact factor: 5.315

9.  Dual-energy CT in early acute pancreatitis: improved detection using iodine quantification.

Authors:  Simon S Martin; Franziska Trapp; Julian L Wichmann; Moritz H Albrecht; Lukas Lenga; James Durden; Christian Booz; Thomas J Vogl; Tommaso D'Angelo
Journal:  Eur Radiol       Date:  2018-11-28       Impact factor: 5.315

10.  A Pilot Clinical Study in Characterization of Malignant Renal-cell Carcinoma Subtype with Contrast-enhanced Ultrasound.

Authors:  Sandeep K Kasoji; Emily H Chang; Lee B Mullin; Wui K Chong; W Kimryn Rathmell; Paul A Dayton
Journal:  Ultrason Imaging       Date:  2016-09-22       Impact factor: 1.578

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.